查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
南美洲和中美洲生物製药市场预测至 2028 年 - 区域分析 - 按产品类型和应用
市场调查报告书
商品编码
1360071

南美洲和中美洲生物製药市场预测至 2028 年 - 区域分析 - 按产品类型和应用

South & Central America Biopharmaceuticals Market Forecast to 2028 -Regional Analysis - by Product Type and Application
出版日期: | 出版商: The Insight Partners | 英文 220 Pages | 订单完成后即时交付

价格

2022年，南美洲和中美洲生物製药市场估值为178.5亿美元，预计到2028年将达到349.7亿美元。预计2022年至2028年复合年增长率为11.9%。

生物製药合约製造推动南美洲和中美洲生物製药市场

合约製造组织 (CMO) 为製药公司带来了许多好处。将任务外包给首席行销长有助于他们减少营运和维护製造设施所需的投资，从而有助于改善净现金流。外包成本更低，并且提高了製造流程的效率。此外，它还允许生物製药公司将资源重新分配到其他重要领域。许多生物製药公司正在重新关注其核心能力，例如研发，导致内部製造能力的剥离，从而导致製造对 CMO 的依赖增加。 CMO 为製药公司提供额外的产能和额外的场地，透过多地点供应策略和备用能力来减轻供应短缺的风险。例如，2022年3月，BioNTech SE 宣布与Regeneron 合作，推进FixVac 候选BNT116 与Libtayo (cemiplimab) 的组合，Libtayo (cemiplimab) 是一种用于治疗晚期非小细胞肺癌(NSCLC) 的PD-1 抑制剂。该合作协议允许两家公司联合进行临床试验，以评估不同晚期非小细胞肺癌患者的联合疗法。因此，生物製药合约製造的日益普及可能会在未来几年促进南美洲和中美洲生物製药市场的成长。

南美洲和中美洲生物製药市场概况

南美洲和中美洲生物製药市场分为巴西、阿根廷以及南美洲和中美洲其他地区。数位放射线摄影在南美洲和中美洲的成像中心变得越来越普遍。癌症的高负担、生物製药技术的不断创新、患癌症风险较高的老年人口的增加以及对各种即将上市的新药物的研究是促进南美洲和中美洲生物製药市场增长的因素。生物製药产品是医学史上最重要的创新之一。然而，这些突破性疗法由于发现和开发需要大量投资而极其昂贵，因此需要更便宜的替代品。南美洲和中美洲为生物药品，特别是生物相似药提供了巨大的机会。在南美洲和中美洲，生物相似药的知识和开发水准很高；因此，本地和外国製药公司对进入该市场进行本地和国际研究、生产和商业化有很大兴趣。生物製品市场将在预测期内快速成长，这主要是由于新分子的发现。製造生物製品所需的先进技术和资源为小型生物技术公司创造了很高的进入障碍。这解释了为什么大型跨国公司主导了该地区的整个生物製品市场。这些公司在研发方面投入巨资，透过不断提供新的创新产品，在生物相似药市场中保持领先地位。南美洲和中美洲生物相似药市场参与者面临的主要挑战与研发成本高、证明产品功效和安全性所需的临床试验以及维持低端价格的需要有关。在南美洲和中美洲，市面上出现的第一个生物相似药产品是胰岛素：粒细胞集落刺激因子（G-CSF）、促红血球生成素和人类生长激素。后来干扰素来到了这个地区，最后是单株抗体。此外，利妥昔单抗、依那塞普和雷妥尤单抗等产品进入南美洲和中美洲市场将扩大生物相似药的市场。由于地理扩张和经济成长，多家全球製药公司选择了巴西市场。由于他们在生物相似药市场的技能，他们将帮助当地公司更快地扩大市场，从而推动该地区南美洲和中美洲的生物製药市场。

南美洲和中美洲生物製药市场收入及 2028 年预测（十亿美元）

南美洲和中美洲生物製药市场细分

南美洲和中美洲生物製药市场按产品类型、应用和国家细分。

根据产品类型，南美洲和中美洲生物製药市场分为单株抗体、重组疫苗、常规疫苗、重组生长因子、纯化蛋白、重组蛋白、重组激素、重组酶、细胞和基因疗法、细胞激素/干扰素/白细胞介素， 和别的。 2022年，单株抗体领域在南美洲和中美洲生物製药市场中占据最大份额。

重组疫苗细分为癌症疫苗、疟疾疫苗、伊波拉疫苗、B型肝炎疫苗、破伤风疫苗、白喉疫苗、霍乱疫苗等。传统疫苗细分为小儿麻痹疫苗、痘疫苗等。重组生长因子片段进一步细分为红血球生成素和粒细胞集落刺激因子。纯化的蛋白质片段进一步细分为白血病抑制因子（LIF）、P53蛋白、P38蛋白等。重组蛋白片段进一步分为血清白蛋白、淀粉样蛋白、防御素和转铁蛋白。重组激素细分为重组人生长激素、重组胰岛素和其他重组激素。重组酶片段进一步分为肠激酶、环化酶、半胱天冬酶和组织蛋白酶。细胞和基因治疗领域进一步细分为同种异体产品、自体产品和非细胞产品。

根据应用，南美洲和中美洲生物製药市场分为肿瘤学、发炎和传染病、自体免疫疾病、代谢失调、荷尔蒙失调和生长障碍、心血管疾病、神经系统疾病等。 2022年，肿瘤学领域在南美洲和中美洲生物製药市场中占据最大份额。

根据国家/地区，南美洲和中美洲生物製药市场分为巴西、阿根廷以及南美洲和中美洲其他地区。 2022年，巴西在南美洲和中美洲生物製药市场中占据最大份额。

艾伯维公司、AGC Biologics AS、安进公司、勃林格殷格翰国际有限公司、百时美施贵宝公司、礼来公司、强生公司、龙沙集团和赛默飞世尔科技公司都是在南部和中部地区营运的领先公司美国生物製药市场。

目录

第 1 章：简介

  • 研究范围
  • Insight Partners 研究报告指南
  • 市场区隔
    • 南美洲和中美洲生物製药市场 - 按产品类型
    • 南美洲和中美洲生物製药市场 - 按应用
    • 南美洲和中美洲生物製药市场 - 按国家/地区

第 2 章：南美洲和中美洲生物製药市场 - 要点

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：南美洲和中美洲生物製药市场 - 市场格局

  • 概述
  • 南美洲和中美洲 PEST 分析
  • 专家意见

第 5 章：南美洲和中美洲生物製药市场 - 主要市场动态

  • 市场驱动因素
    • 在癌症治疗的应用不断增加
    • 治疗罕见疾病的潜力
  • 市场限制
    • 製造基础设施成本高昂
  • 市场机会
    • 加速临床试验
  • 未来的趋势
    • 生物製药合约製造
  • 影响分析

第 6 章：生物製药市场 - 南美洲和中美洲分析

  • 南美洲和中美洲生物製药市场收入预测与分析

第 7 章：南美洲和中美洲生物製药市场 - 2028 年收入和预测 - 按产品类型

  • 概述
  • 2021 年和 2028 年按产品类型分類的生物製药市场收入份额 (%)
  • 单株抗体
  • 重组疫苗
  • 常规疫苗
  • 重组生长因子
  • 纯化蛋白质
  • 重组蛋白
  • 重组激素
  • 重组酵素
  • 细胞和基因疗法
  • 细胞激素/干扰素/白血球介素
  • 其他（基于 mRNA 的疗法等）

第 8 章：2028 年南美洲和中美洲生物製药市场分析和预测 -按应用

  • 概述
  • 南美洲和中美洲生物製药市场，按应用分类 2021 年和 2028 年 (%)
  • 肿瘤学
  • 发炎和传染病
  • 自体免疫疾病
  • 代谢紊乱
  • 荷尔蒙失调与生长障碍
  • 心血管疾病
  • 神经系统疾病
  • 其他治疗应用

第 9 章：南美洲和中美洲生物製药市场 - 2028 年收入和预测 - 国家分析

    • 南美洲和中美洲
      • 巴西
      • 阿根廷
      • 南美洲和中美洲其他地区

第 10 章：南美洲和中美洲生物製药市场 - 产业格局

  • 概述
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 11 章：公司简介

  • Amgen Inc
  • AbbVie Inc
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Thermo Fisher Scientific Inc
  • AGC Biologics AS
  • Lonza Group AG

第 12 章：附录

  • 关于 Insight Partners
  • 专业术语
Product Code: BMIRE00028654

The South & Central America biopharmaceuticals market was valued at US$ 17.85 billion in 2022 and is projected to reach US$ 34.97 billion by 2028. It is estimated to grow at a CAGR of 11.9% from 2022 to 2028.

Contract Manufacturing of Biopharmaceuticals Drives South & Central America Biopharmaceuticals Market

Contract manufacturing organizations (CMOs) bring many benefits to the table for pharmaceutical companies. Outsourcing tasks to CMOs help them reduce investments required for operating and maintaining manufacturing facilities, thereby aiding improvements in the net cash flow. Outsourcing is cheaper and increases the efficiency of manufacturing processes. Also, it allows biopharmaceutical companies to redirect resources to other important areas. Many biopharmaceutical companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, which subsequently results in an increased dependence on CMOs for manufacturing. CMOs provide additional capacities and offer additional sites for pharmaceutical companies to mitigate the risk of supply shortages through multisite supply strategies and backup capacities. For instance, in March 2022, BioNTech SE announced a collaboration with Regeneron to advance the FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor for treating advanced non-small cell lung cancer (NSCLC). The collaboration agreement allows the companies to jointly conduct clinical trials to evaluate the combination therapy in different patients suffering from advanced NSCLC. Thus, the increasing popularity of biopharmaceuticals contract manufacturing is likely to catalyze the growth of the South & Central America biopharmaceuticals market in the coming years.

South & Central America Biopharmaceuticals Market Overview

The South & Central America Biopharmaceuticals market is segmented into Brazil, Argentina, and the Rest of South & Central America. Digital radiography is becoming more prevalent in imaging centers across South & Central America. The high burden of cancer, ongoing innovations in biopharmaceuticals technologies, increase in the geriatric population that is at a greater risk of cancer, and research studies on various new upcoming medicines are among the factors contributing to the growth of biopharmaceuticals market in South & Central America. Biopharmaceuticals products are among the most important innovations in medical history. However, these breakthrough therapies, which are extremely expensive due to the large investments required for their discovery and development, call for cheaper alternatives. South & Central America provides a great opportunity for biologic medicines, particularly biosimilars. In South & Central America, there is a high level of knowledge and development of biosimilars; hence, there is a great interest in local and foreign pharmaceutical companies to enter the market to research, manufacture, and commercialize locally and internationally. The biologics market is set to grow rapidly over the forecast period, mainly due to the discovery of new molecules. The advanced technology and resources required to manufacture biologics create high barriers to entry for small biotech companies. This explains why large multinational companies dominate the entire biologics market in the region. These companies invest heavily in R&D to stay ahead in the biosimilar market by constantly offering new innovative products. The main challenges faced by participants in the South & Central America biosimilar market are related to the high cost of research and development, the clinical trials required to prove product efficacy and safety, and the need to maintain low-end prices. In South & Central America, the first biosimilar product to appear on the market was insulin: granulocyte colony-stimulating factor (G-CSF), erythropoietin, and human growth hormone. Interferon later came to the region, and finally, monoclonal antibodies. In addition, the market entry of products such as rituximab, etanercep, and racotunumab in South & Central America would expand the market for biosimilars. Several global pharmaceutical companies have chosen the Brazil market due to their geographic expansion and growing economy. Because of their skills in the biosimilars market, they will help expand the market faster with only local companies, thereby boosting the South & Central America biopharmaceuticals market in the region.

South & Central America Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Billion)

South & Central America biopharmaceuticals market Segmentation

The South & Central America biopharmaceuticals market is segmented into product type, application, and country.

Based on product type, the South & Central America biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the South & Central America biopharmaceuticals market.

The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, Ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.

Based on application, the South & Central America biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the South & Central America biopharmaceuticals market.

Based on country, the South & Central America biopharmaceuticals market is segmented into Brazil, Argentina, and the Rest of South & Central America. In 2022, Brazil held the largest share of the South & Central America biopharmaceuticals market.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, and Thermo Fisher Scientific Inc are among the leading companies operating in the South & Central America biopharmaceuticals market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America biopharmaceutical market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the South & Central America biopharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies
  • develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the biopharmaceutical market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 South & Central America Biopharmaceuticals Market - by Product Type
    • 1.3.2 South & Central America Biopharmaceuticals Market - by Application
    • 1.3.3 South & Central America Biopharmaceuticals Market - by Country

2. South & Central America Biopharmaceuticals Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. South & Central America Biopharmaceuticals Market - Market Landscape

  • 4.1 Overview
  • 4.2 South & Central America PEST Analysis
  • 4.3 Expert's Opinion

5. South & Central America Biopharmaceuticals Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Application in Cancer Therapeutics
    • 5.1.2 Potential to Treat Rare Diseases
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Manufacturing Infrastructure
  • 5.3 Market Opportunities
    • 5.3.1 Accelerated Clinical Trials
  • 5.4 Future Trends
    • 5.4.1 Contract Manufacturing of Biopharmaceuticals
  • 5.5 Impact Analysis

6. Biopharmaceuticals Market - South & Central America Analysis

  • 6.1 South & Central America Biopharmaceuticals Market Revenue Forecast and Analysis

7. South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 - by Product Type

  • 7.1 Overview
  • 7.2 Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
  • 7.3 Monoclonal Antibodies
    • 7.3.1 Overview
    • 7.3.2 Monoclonal Antibodies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Recombinant Vaccines
    • 7.4.1 Overview
    • 7.4.2 Recombinant Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.1 Cancer Vaccine
        • 7.4.2.1.1 Overview
        • 7.4.2.1.2 Cancer Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.2 Malaria Vaccine
        • 7.4.2.2.1 Overview
        • 7.4.2.2.2 Malaria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.3 Ebola Vaccine
        • 7.4.2.3.1 Overview
        • 7.4.2.3.2 Ebola Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.4 Hepatitis-B Vaccine
        • 7.4.2.4.1 Overview
        • 7.4.2.4.2 Hepatitis-B Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.5 Tetanus Vaccine
        • 7.4.2.5.1 Overview
        • 7.4.2.5.2 Tetanus Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.6 Diphtheria Vaccine
        • 7.4.2.6.1 Overview
        • 7.4.2.6.2 Diphtheria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.7 Cholera Vaccine
        • 7.4.2.7.1 Overview
        • 7.4.2.7.2 Cholera Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.8 Others
        • 7.4.2.8.1 Overview
        • 7.4.2.8.2 Others: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Conventional Vaccines
    • 7.5.1 Overview
    • 7.5.2 Conventional Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.1 Polio Vaccine
        • 7.5.2.1.1 Overview
        • 7.5.2.1.2 Polio Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.2 Pox Vaccine
        • 7.5.2.2.1 Overview
        • 7.5.2.2.2 Pox Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.3 Other Conventional Vaccine
        • 7.5.2.3.1 Overview
        • 7.5.2.3.2 Other Conventional Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Recombinant Growth Factors
    • 7.6.1 Overview
    • 7.6.2 Recombinant Growth Factors: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.1 Erythropoietin
        • 7.6.2.1.1 Overview
        • 7.6.2.1.2 Erythropoietin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.2 Granulocyte Colony Stimulating Factor
        • 7.6.2.2.1 Overview
        • 7.6.2.2.2 Granulocyte Colony Stimulating Factor: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.7 Purified Proteins
    • 7.7.1 Overview
    • 7.7.2 Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.1 Leukemia Inhibitory Factor (LIF)
        • 7.7.2.1.1 Overview
        • 7.7.2.1.2 Leukemia Inhibitory Factor (LIF): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.2 P53 Protein
        • 7.7.2.2.1 Overview
        • 7.7.2.2.2 P53 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.3 P38 Protein
        • 7.7.2.3.1 Overview
        • 7.7.2.3.2 P38 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.4 Other Purified Proteins
        • 7.7.2.4.1 Overview
        • 7.7.2.4.2 Other Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.8 Recombinant Proteins
    • 7.8.1 Overview
    • 7.8.2 Recombinant Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.1 Serum Albumin
        • 7.8.2.1.1 Overview
        • 7.8.2.1.2 Serum Albumin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.2 Amyloid Protein
        • 7.8.2.2.1 Overview
        • 7.8.2.2.2 Amyloid Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.3 Defensin
        • 7.8.2.3.1 Overview
        • 7.8.2.3.2 Defensin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.4 Transferrin
        • 7.8.2.4.1 Overview
        • 7.8.2.4.2 Transferrin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.9 Recombinant Hormones
    • 7.9.1 Overview
    • 7.9.2 Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.1 Recombinant Human Growth Hormones
        • 7.9.2.1.1 Overview
        • 7.9.2.1.2 Recombinant Human Growth Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.2 Recombinant Insulin
        • 7.9.2.2.1 Overview
        • 7.9.2.2.2 Recombinant Insulin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.3 Other Recombinant Hormones
        • 7.9.2.3.1 Overview
        • 7.9.2.3.2 Other Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.10 Recombinant Enzymes
    • 7.10.1 Overview
    • 7.10.2 Recombinant Enzymes: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.1 Enterokinase
        • 7.10.2.1.1 Overview
        • 7.10.2.1.2 Enterokinase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.2 Cyclase
        • 7.10.2.2.1 Overview
        • 7.10.2.2.2 Cyclase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.3 Caspase
        • 7.10.2.3.1 Overview
        • 7.10.2.3.2 Caspase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.4 Cathepsin
        • 7.10.2.4.1 Overview
        • 7.10.2.4.2 Cathepsin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.11 Cell and Gene Therapies
    • 7.11.1 Overview
    • 7.11.2 Cell and Gene Therapies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.1 Allogenic Products
        • 7.11.2.1.1 Overview
        • 7.11.2.1.2 Allogenic Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.2 Autologous Products
        • 7.11.2.2.1 Overview
        • 7.11.2.2.2 Autologous Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.3 Acellular Products
        • 7.11.2.3.1 Overview
        • 7.11.2.3.2 Acellular Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.12 Cytokines/Interferon/Interleukins
    • 7.12.1 Overview
    • 7.12.2 Cytokines/Interferon/Interleukins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.13 Others (mRNA Based Therapeutics, etc.)
    • 7.13.1 Overview
    • 7.13.2 Others (mRNA Based Therapeutics, etc.): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

8. South & Central America Biopharmaceuticals Market Analysis and Forecasts to 2028 - by Application

  • 8.1 Overview
  • 8.2 South & Central America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
  • 8.3 Oncology
    • 8.3.1 Overview
    • 8.3.2 Oncology: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Inflammatory and Infectious Diseases
    • 8.4.1 Overview
    • 8.4.2 Inflammatory and Infectious Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.5 Autoimmune Disorders
    • 8.5.1 Overview
    • 8.5.2 Autoimmune Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.6 Metabolic Disorders
    • 8.6.1 Overview
    • 8.6.2 Metabolic Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.7 Hormonal Disorders and Growth Failure
    • 8.7.1 Overview
    • 8.7.2 Hormonal Disorders and Growth Failure: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.8 Cardiovascular Diseases
    • 8.8.1 Overview
    • 8.8.2 Cardiovascular Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.9 Neurological Diseases
    • 8.9.1 Overview
    • 8.9.2 Neurological Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.10 Other Therapeutic Applications
    • 8.10.1 Overview
    • 8.10.2 Other Therapeutic Applications: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

9. South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 - Country Analysis

  • 9.1 Overview
    • 9.1.1 South & Central America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
      • 9.1.1.1 Brazil: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.1.1 Brazil: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.1.1.1 Brazil: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.1.1.2 Brazil: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.1.1.3 Brazil: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.1.1.4 Brazil: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.1.1.5 Brazil: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.1.1.6 Brazil: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.1.1.7 Brazil: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.1.1.8 Brazil: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.1.2 Brazil: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
      • 9.1.1.2 Argentina: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.2.1 Argentina: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.2.1.1 Argentina: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.2.1.2 Argentina: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.2.1.3 Argentina: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.2.1.4 Argentina: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.2.1.5 Argentina: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.2.1.6 Argentina: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.2.1.7 Argentina: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.2.1.8 Argentina: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.2.2 Argentina: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
      • 9.1.1.3 Rest of South & Central America: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.3.1 Rest of South & Central America: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.3.1.1 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.3.1.2 Rest of South & Central America: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.3.1.3 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.3.1.4 Rest of South & Central America: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.3.1.5 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.3.1.6 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.3.1.7 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.3.1.8 Rest of South & Central America: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.3.2 Rest of South & Central America: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)

10. South & Central America Biopharmaceuticals Market - Industry Landscape

  • 10.1 Overview
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview

11. Company Profiles

  • 11.1 Amgen Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 AbbVie Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Eli Lilly and Co
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Bristol-Myers Squibb Co
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Johnson & Johnson
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Boehringer Ingelheim International GmbH
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Thermo Fisher Scientific Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 AGC Biologics AS
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Lonza Group AG
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. Brazil Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. Brazil Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. Brazil Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. Brazil Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. Brazil Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. Brazil Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. Brazil Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. Brazil Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. Brazil Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. Brazil Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. Argentina Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 13. Argentina Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Argentina Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. Argentina Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Argentina Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Argentina Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Argentina Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
  • Table 19. Argentina Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
  • Table 20. Argentina Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
  • Table 21. Argentina Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 22. Rest of South & Central America Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 23. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 24. Rest of South & Central America Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 25. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
  • Table 26. Rest of South & Central America Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 27. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 28. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
  • Table 29. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
  • Table 30. Rest of South & Central America Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
  • Table 31. Rest of South & Central America Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 32. Recent Organic Growth Strategies in Biopharmaceuticals Market
  • Table 33. Recent Inorganic Growth Strategies in the South & Central America biopharmaceuticals market
  • Table 34. Glossary of Terms

List Of Figures

  • Figure 1. South & Central America Biopharmaceuticals Market Segmentation
  • Figure 2. South & Central America Biopharmaceuticals Market, by Country
  • Figure 3. South & Central America Biopharmaceuticals Market Overview
  • Figure 4. Monoclonal Antibodies Segment Held Largest Share of Product Type Segment in South & Central America Biopharmaceuticals Market
  • Figure 5. Brazil Expected to Show Remarkable Growth During Forecast Period
  • Figure 6. South & Central America: PEST Analysis
  • Figure 7. Experts\' Opinion
  • Figure 8. South & Central America Biopharmaceuticals Market: Impact Analysis of Drivers and Restraints
  • Figure 9. South & Central America Biopharmaceuticals Market - Revenue Forecast and Analysis - 2020-2028
  • Figure 10. Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
  • Figure 11. Monoclonal Antibodies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. Recombinant Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. Cancer Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. Malaria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 15. Ebola Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 16. Hepatitis-B Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. Tetanus Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 18. Diphtheria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 19. Cholera Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Others: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Conventional Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. Polio Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 23. Pox Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Other Conventional Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. Recombinant Growth Factors: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. Erythropoietin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 27. Granulocyte Colony Stimulating Factor: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 28. Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. Leukemia Inhibitory Factor (LIF): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. P53 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 31. P38 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 32. Other Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Recombinant Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. Serum Albumin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 35. Amyloid Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 36. Defensin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 37. Transferrin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 38. Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 39. Recombinant Human Growth Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 40. Recombinant Insulin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 41. Other Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 42. Recombinant Enzymes: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 43. Enterokinase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 44. Cyclase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 45. Caspase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 46. Cathepsin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 47. Cell and Gene Therapies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 48. Allogenic Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 49. Autologous Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 50. Acellular Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 51. Cytokines/Interferon/Interleukins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 52. Others (mRNA Based Therapeutics, etc.): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 53. South & Central America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
  • Figure 54. Oncology: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 55. Inflammatory and Infectious Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 56. Autoimmune Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 57. Metabolic Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 58. Hormonal Disorders and Growth Failure: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 59. Cardiovascular Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 60. Neurological Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 61. Other Therapeutic Applications: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 62. South & Central America: Biopharmaceuticals Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 63. South & Central America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
  • Figure 64. Brazil: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 65. Argentina: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 66. Rest of South & Central America: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)